Myriad Genetics (NASDAQ:MYGN) Given New $6.00 Price Target at Wells Fargo & Company

Myriad Genetics (NASDAQ:MYGN) had its price target decreased by Wells Fargo & Company from $6.50 to $6.00 in a research note published on Tuesday,Benzinga reports. Wells Fargo & Company currently has an equal weight rating on the stock.

Other research analysts have also issued reports about the company. Weiss Ratings reissued a “sell (d-)” rating on shares of Myriad Genetics in a report on Monday, December 29th. Piper Sandler cut their price objective on shares of Myriad Genetics from $9.00 to $8.50 and set an “overweight” rating for the company in a research report on Tuesday, November 11th. TD Cowen restated a “hold” rating on shares of Myriad Genetics in a report on Tuesday, November 4th. Zacks Research lowered Myriad Genetics from a “hold” rating to a “strong sell” rating in a research note on Monday, January 19th. Finally, UBS Group dropped their price target on Myriad Genetics from $8.00 to $6.00 and set a “neutral” rating for the company in a report on Tuesday. Four equities research analysts have rated the stock with a Buy rating, six have issued a Hold rating and three have assigned a Sell rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Hold” and an average price target of $9.17.

Myriad Genetics Trading Up 1.1%

Shares of Myriad Genetics stock opened at $4.43 on Tuesday. The stock has a market cap of $412.92 million, a P/E ratio of -1.12 and a beta of 1.90. Myriad Genetics has a 12-month low of $3.76 and a 12-month high of $12.28. The business’s 50 day moving average is $5.73 and its 200-day moving average is $6.63. The company has a quick ratio of 2.12, a current ratio of 2.33 and a debt-to-equity ratio of 0.32.

Myriad Genetics (NASDAQ:MYGN) last released its quarterly earnings data on Monday, February 23rd. The company reported $0.04 earnings per share for the quarter, topping the consensus estimate of ($0.02) by $0.06. The company had revenue of $209.80 million for the quarter, compared to analyst estimates of $207.57 million. Myriad Genetics had a negative net margin of 44.38% and a negative return on equity of 5.96%. Myriad Genetics’s revenue for the quarter was down .4% compared to the same quarter last year. During the same period in the previous year, the business earned $0.03 EPS. Equities research analysts predict that Myriad Genetics will post -0.3 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Myriad Genetics

Several hedge funds have recently bought and sold shares of MYGN. Invesco Ltd. lifted its stake in Myriad Genetics by 2.4% during the fourth quarter. Invesco Ltd. now owns 507,180 shares of the company’s stock worth $3,119,000 after purchasing an additional 12,026 shares during the last quarter. Mercer Global Advisors Inc. ADV lifted its holdings in shares of Myriad Genetics by 62.7% in the fourth quarter. Mercer Global Advisors Inc. ADV now owns 26,886 shares of the company’s stock worth $165,000 after acquiring an additional 10,359 shares during the last quarter. Vestal Point Capital LP boosted its stake in shares of Myriad Genetics by 103.8% in the 4th quarter. Vestal Point Capital LP now owns 1,223,000 shares of the company’s stock valued at $7,521,000 after purchasing an additional 623,000 shares in the last quarter. Tudor Investment Corp ET AL bought a new stake in shares of Myriad Genetics during the 4th quarter valued at approximately $276,000. Finally, Oxford Asset Management LLP bought a new stake in shares of Myriad Genetics during the 4th quarter valued at approximately $143,000. 99.02% of the stock is owned by institutional investors.

Myriad Genetics News Summary

Here are the key news stories impacting Myriad Genetics this week:

• Positive Sentiment: Q4 results beat expectations — Myriad reported EPS of $0.04 vs. a consensus loss (~$‑0.02) and revenue of $209.8M (above estimates), a key catalyst for the stock rally. Myriad Genetics Beats Q4 Expectations, Shares Surge
• Positive Sentiment: Company reiterated FY‑2026 guidance and gave Q1 revenue growth outlook of +2%–4% Y/Y, plus provided a slide deck and call details — supporting management’s message of stabilized execution. Company Press Release / Guidance
• Positive Sentiment: Operating cash flow and cash balances improved (Quiver reports cash provided by ops +60% Y/Y to $10.6M; cash & equivalents ~$149.6M), easing short‑term liquidity concerns. QuiverQuant: Q4 Results and Balance Sheet Items
• Neutral Sentiment: Analyst views are mixed: Wells Fargo cut its price target to $6.00 and holds an “Equal Weight” rating (new PT still implies upside), while TD Cowen maintained a Hold with a $7 target — expect continued divergence in street commentary. Wells Fargo Price Target Note
• Negative Sentiment: Gross margin slipped and mental‑health test sales declined, which could pressure profitability and growth if trends persist. Zacks: Gross Margin Down
• Negative Sentiment: Some analysts remain bearish — Bank of America reiterated a Sell citing execution and reimbursement risks and set a $4.00 target, highlighting downside risk if reimbursement or rollout issues resurface. TipRanks: BofA Sell Rating

Myriad Genetics Company Profile

Myriad Genetics (NASDAQ: MYGN) is a molecular diagnostics company that develops and commercializes genetic tests designed to assess an individual’s risk for various hereditary conditions and to guide personalized treatment decisions. The company’s core business centers on predictive medicine, with a focus on hereditary cancer risk assessment through its flagship BRACAnalysis® test for BRCA1 and BRCA2 gene mutations. In addition to oncology, Myriad offers tests in women’s health, neurology and pharmacogenomics to support more informed clinical decision-making.

Among its product offerings are the myRisk® Hereditary Cancer test, which screens for mutations across multiple cancer-related genes, and Prequel®, a non-invasive prenatal test for assessing fetal chromosomal abnormalities.